Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel–Lindau Gene Mutation Status

European Urology

Volumn 70, Issue 4, 2016, Pages 623-632

  Messai, Yosra ^a,b   Gad, Sophie ^a,b,c   Noman, Muhammad Zaeem ^a,b   Le Teuff, Gwenael ^b,d   Couve, Sophie ^a,b,c   Janji, Bassam ^e   Kammerer, Solenne Florence ^f,g   Rioux Leclerc, Nathalie ^f,g   Hasmim, Meriem ^a,b   Ferlicot, Sophie ^a,b,h   Baud, Véronique ^b,i,j   Mejean, Arnaud ^k   Mole, David Robert ^l   Richard, Stéphane ^a,b,c   Eggermont, Alexander M M ^m   Albiges, Laurence ^a,b,n   Mami Chouaib, Fathia ^a,b   Escudier, Bernard ^a,b,n   Chouaib, Salem ^a,b  

^a Faculty of Medicine University of Paris Sud   (France)

^b INSERM   (France)

^c PSL RESEARCH UNIVERSITY   (France)

^d Department of Biostatistics and Epidemiology ^*  (France)

^e LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^f RENNES UNIVERSITY HOSPITAL   (France)

^g UNIVERSITÉ DE RENNES 1   (France)

^h UNIVERSITÉ PARIS SACLAY   (France)

ⁱ CNRS   (France)

^j UNIVERSITÉ PARIS DESCARTES   (France)

^k HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^l UNIVERSITY OF OXFORD   (United Kingdom)

^m Cancer Institute Gustave Roussy Cancer Campus Grand Paris   (France)

ⁿ Gustave Roussy Cancer Campus   (France)

more..

Author keywords

ccRCC; HIF 2 ; PD L1; VHL mutations

Indexed keywords

CARBONATE DEHYDRATASE IX; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1; VASCULOTROPIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CD274 PROTEIN, HUMAN; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; VON HIPPEL LINDAU PROTEIN;

ALLELE; ARTICLE; CANCER IMMUNOTHERAPY; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GENE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRON; KIDNEY CARCINOMA; LOSS OF FUNCTION MUTATION; LUCIFERASE ASSAY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN STABILITY; RENAL CANCER CELL LINE; TRANSCRIPTION INITIATION; VON HIPPERL LINDAU GENE; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOSITY LOSS; KIDNEY TUMOR; METABOLISM; RENAL CELL CARCINOMA; TUMOR CELL LINE;

ALLELES; B7-H1 ANTIGEN; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; LOSS OF FUNCTION MUTATION; LOSS OF HETEROZYGOSITY; MALE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84975482619     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.11.029     Document Type: Article

References (28)

1. [1] Gupta, K., Miller, J.D., Li, J.Z., Russell, M.W., Charbonneau, C., Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev 34 (2008), 193–205.
2. [2] Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.M., Orcutt, M.L., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260 (1993), 1317–1320.
3. [3] Gnarra, J.R., Tory, K., Weng, Y., Schmidt, L., Wei, M.H., Li, H., et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7 (1994), 85–90.
4. [4] Rechsteiner, M.P., von Teichman, A., Nowicka, A., Sulser, T., Schraml, P., Moch, H., VHL gene mutations and their effects on hypoxia inducible factor HIFalpha: identification of potential driver and passenger mutations. Cancer Res 71 (2011), 5500–5511.
5. [5] Couve, S., Ladroue, C., Laine, E., Mahtouk, K., Guegan, J., Gad, S., et al. Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis. Cancer Res 74 (2014), 6554–6564.
6. [6] Young, A.C., Craven, R.A., Cohen, D., Taylor, C., Booth, C., Harnden, P., et al. Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res 15 (2009), 7582–7592.
7. [7] Sato, Y., Yoshizato, T., Shiraishi, Y., Maekawa, S., Okuno, Y., Kamura, T., et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 45 (2013), 860–867.
8. [8] Kaelin, W.G. Jr., The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8 (2008), 865–873.
9. [9] Escudier, B., Heng, D.Y., Smyth-Medina, A., Porta, C., Considerations for the design of future clinical trials in metastatic renal cell carcinoma. Clin Genitourin Cancer 12 (2014), 1–12.
10. [10] Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12 (2012), 252–264.
11. [11] Wu, P., Wu, D., Li, L., Chai, Y., Huang, J., PD-L1 and survival in solid tumors: A meta-analysis. PloS One, 10, 2015, e0131403.
12. [12] Noman, M.Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 211 (2014), 781–790.
13. [13] Thompson, R.H., Dong, H., Kwon, E.D., Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin Cancer Res 13 (2007), S709–S715.
14. [14] Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
15. [15] Brahmer, J.R., Tykodi, S.S., Chow, L.Q., Hwu, W.J., Topalian, S.L., Hwu, P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (2012), 2455–2465.
16. [16] Motzer, R.J., Rini, B.I., McDermott, D.F., Redman, B.G., Kuzel, T.M., Harrison, M.R., et al. Nivolumab for metastatic renal cell carcinoma: Results of a randomized phase II trial. J Clin Oncol 33 (2015), 1430–1437.
17. [17] Messai, Y., Noman, M.Z., Hasmim, M., Janji, B., Tittarelli, A., Boutet, M., et al. ITPR1 protects renal cancer cells against natural killer cells by inducing autophagy. Cancer Res 74 (2014), 6820–6832.
18. [18] Jacque, E., Billot, K., Authier, H., Bordereaux, D., Baud, V., RelB inhibits cell proliferation and tumor growth through p53 transcriptional activation. Oncogene 32 (2013), 2661–2669.
19. [19] Richard, S., Gardie, B., Couve, S., Gad, S., Von Hippel-Lindau: how a rare disease illuminates cancer biology. Semin Cancer Biol 23 (2013), 26–37.
20. [20] Maher, E.R., Neumann, H.P., Richard, S., von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet 19 (2011), 617–623.
21. [21] Balan, M., Mier y Teran, E., Waaga-Gasser, A.M., Gasser, M., Choueiri, T.K., Freeman, G., et al. Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. J Biol Chem 290 (2015), 8110–8120.
22. [22] Kondo, K., Kim, W.Y., Lechpammer, M., Kaelin, W.G. Jr., Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol, 1, 2003, E83.
23. [23] Gordan, J.D., Lal, P., Dondeti, V.R., Letrero, R., Parekh, K.N., Oquendo, C.E., et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14 (2008), 435–446.
24. [24] duPre, S.A., Redelman, D., Hunter, K.W. Jr., Microenvironment of the murine mammary carcinoma 4T1: endogenous IFN-gamma affects tumor phenotype, growth, and metastasis. Exp Mol Pathol 85 (2008), 174–188.
25. [25] Curiel, T.J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9 (2003), 562–567.
26. [26] Topalian, S.L., Drake, C.G., Pardoll, D.M., Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27 (2015), 450–461.
27. [27] Liu, X.D., Hoang, A., Zhou, L., Kalra, S., Yetil, A., Sun, M., et al. Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. Cancer Immunol Res, 3, 2015, 1017.
28. [28] Giraldo, N.A., Becht, E., Pages, F., Skliris, G., Verkarre, V., Vano, Y., et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin Cancer Res 21 (2015), 3031–3040.